CNS Delivery Denali's TransportVehicle platform enables crossing the blood-br brain barrier to deliver therapies for neurodegenerative and lysosomal storage diseases, creating opportunities to engage specialty pharmacies, patient access programs, and distribution partners for complex CNS medicines such as AVLAYAH; connections with Orsini signal a pathway to scalable access for presymptomatic and pediatric patients in need.

Manufacturing Growth Expansion to a Salt Lake City biomanufacturing facility indicates scale-up capability and potential for CDMO partnerships, process development, and fill finish services to support DNL programs and potential external collaborations, reducing supply risk for ongoing clinical trials and future commercialization.

Clinical Partnerships Active CNS and rare disease pipeline (DNL593 brain progranulin delivery; DNL343 ALS data; MPS II treatment) suggests opportunities to engage CROs, biomarker labs, imaging and regulatory service providers to accelerate trials, global regulatory submissions, and companion diagnostics.

Strategic Alliances History of partnerships and a recent termination with Takeda highlights a dynamic environment for co development or licensing of TransportVehicle platform or DNL assets; target potential pharma alliances for broader indications, co development, or regional commercialization.

Market Access Significant revenue and substantial funding position Denali to invest in market access, pharmacovigilance, and payer strategy services; potential to offer or co create patient support programs, HTA ready data packages, and international expansion services with payers and clinics.